Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 603

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis

Open access
Bolaños-Meade, Javier, Hamadani, Mehdi, Wu, Juan, Al Malki, Monzr M., Martens, Michael J., Runaas, Lyndsey, Elmariah, Hany, Rezvani, Andrew R., Gooptu, Mahasweta, Larkin, Karilyn T., Shaffer, Brian C., El Jurdi, Najla, Loren, Alison W., Solh, Melhem, Hall, Aric C., Alousi, Amin M., Jamy, Omer H., Perales, Miguel-Angel, Yao, Janny M., Applegate, Kristy, Bhatt, Ami S., Kean, Leslie S., Efebera, Yvonne A., Reshef, Ran, Clark, William, DiFronzo, Nancy L., Leifer, Eric, Horowitz, Mary M., Jones, Richard J., Holtan, Shernan G.·2023·New England Journal of Medicine

Abstract

In patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT), a calcineurin inhibitor plus methotrexate has been a standard prophylaxis against graft-versus-host disease (GVHD). A phase 2 study indicated the potential superiority of a post-transplantation regimen of cyclophosphamide, tacrolimus, and mycophenolate mofetil. Download a PDF of the Research Summary. In a phase 3 trial, we randomly assigned adults with hematologic cancers in a 1:1 ratio to receive cyclophosphamide–tacrolimus–mycophenolate mofetil (experimental prophylaxis) or tacrolimus–methotrexate (standard prophylaxis). The patients underwent HSCT from an HLA-matched related donor or a matched or 7/8 mismatched (i.e., mismatched at only one of the HLA-A, HLA-B, HLA-C, and HLA-DRB1 loci) unrelated donor, after reduced-intensity conditioning. The primary end point was GVHD-free, relapse-free survival at 1 year, assessed in a time-to-event analysis, with events defined as grade III or IV acute GVHD, chronic GVHD warranting systemic immunosuppression, disease relapse or progression, and death from any cause. In a multivariate Cox regression analysis, GVHD-free, relapse-free survival was significantly more common among the 214 patients in the experimental-prophylaxis group than among the 217 patients in the standard-prophylaxis group (hazard ratio for grade III or IV acute GVHD, chronic GVHD, disease relapse or progression, or death, 0.64; 95% confidence interval [CI], 0.49 to 0.83; P=0.001). At 1 year, the adjusted GVHD-free, relapse-free survival was 52.7% (95% CI, 45.8 to 59.2) with experimental prophylaxis and 34.9% (95% CI, 28.6 to 41.3) with standard prophylaxis. Patients in the experimental-prophylaxis group appeared to have less severe acute or chronic GVHD and a higher incidence of immunosuppression-free survival at 1 year. Overall and disease-free survival, relapse, transplantation-related death, and engraftment did not differ substantially between the groups. Among patients undergoing allogeneic HLA-matched HSCT with reduced-intensity conditioning, GVHD-free, relapse-free survival at 1 year was significantly more common among those who received cyclophosphamide–tacrolimus–mycophenolate mofetil than among those who received tacrolimus–methotrexate. (Funded by the National Heart, Lung, and Blood Institute and others; BMT CTN 1703 ClinicalTrials.gov number, NCT03959241.) QUICK TAKE VIDEO SUMMARYGraft-versus-Host Disease Prophylaxis 02:16

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2215943

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Metadata

Authors
Bolaños-Meade, J., Hamadani, M., Wu, J., Al Malki, M. M., Martens, M. J., Runaas, L., Elmariah, H., Rezvani, A. R., Gooptu, M., Larkin, K. T., Shaffer, B. C., El Jurdi, N., Loren, A. W., Solh, M., Hall, A. C., Alousi, A. M., Jamy, O. H., Perales, M.-A., Yao, J. M., Applegate, K., Bhatt, A. S., Kean, L. S., Efebera, Y. A., Reshef, R., Clark, W., DiFronzo, N. L., Leifer, E., Horowitz, M. M., Jones, R. J., & Holtan, S. G.
Venue
New England Journal of Medicine
Published
2023-06-22
Volume
388
Issue
25
Pages
2338-2348
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4381487086
Cited by
603
References
24
FWCI
107.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. https://app.cochat.ai/papers/10.1056/nejmoa2215943
The paper
Bolaños-Meade, J., Hamadani, M., Wu, J., Al Malki, M. M., Martens, M. J., Runaas, L., Elmariah, H., Rezvani, A. R., Gooptu, M., Larkin, K. T., Shaffer, B. C., El Jurdi, N., Loren, A. W., Solh, M., Hall, A. C., Alousi, A. M., Jamy, O. H., Perales, M.-A., Yao, J. M., . . . Holtan, S. G. (2023). Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2215943

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.